We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Study Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients
News

Study Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients

Study Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients
News

Study Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Study Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics, Ltd. has announced that the results of a joint study with the NYU Langone Medical Center were published online on February 16th, 2010, and are set to be published in the March 1st issue of the American Association for Cancer Research’s journal, Cancer Research.

The study, “Hsa-Mir-29c* is Linked to the Prognosis of Malignant Pleural Mesothelioma,” demonstrates the potential of a single microRNA to act as an independent prognostic factor for time to progression as well as survival after surgery.

In the study, 142 MPM tumors were analyzed for microRNA expression levels using Rosetta Genomics’ proprietary microRNA-based array and qRT-PCR technologies. The results clearly demonstrate that higher levels of miR-29c* in MPM predict a more favorable prognosis. Not only was the microRNA able to separate MPM patients by time to progression after surgery, but it also stratified these patients by their survival.

When examining Time to Progression (TTP) of MPM, the expression level of miR-29c* enabled the identification of two groups with significantly different median TTP: 4 months versus 14 months in the study’s training set, and 5.5 months versus 12.8 months in the study’s test set.

When examining survival rates for MPM, the expression level of miR-29c* enabled the identification of two groups as well: median survival of 8 months versus 32 months in the study’s training set, and median survival of 9.1 months versus 21.6 months in the study’s test set. This new diagnostic capability may help physicians apply more aggressive therapeutic modalities to the poor prognosis group.

Furthermore, the study found that over-expression of miR-29c* in mesothelioma cell lines resulted in significantly decreased proliferation, migration, invasion and colony formation.
Advertisement